Comparative Analysis of the TCR Repertoire in Bone Marrow CD8+ T Cells From Patients With Acute Myeloid Leukemia, Myelodysplastic Neoplasms, and Chronic Myelomonocytic Leukemia

Eur J Immunol. 2025 Jun;55(6):e51796. doi: 10.1002/eji.202551796.

Abstract

Bone marrow CD8+ T cells from patients with MDS and CMML show decreased TCR diversity compared to AML. Treatment with the hypomethylating agent azacitidine in MDS and CMML alters TCR repertoire of CD8+ T cells without affecting TCR diversity.

Keywords: CD8+ T cells; TCR repertoire; acute myeloid leukemia (AML); chronic myelomonocytic leukemia (CMML); myelodysplastic neoplasms (MDS).

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Azacitidine / pharmacology
  • Azacitidine / therapeutic use
  • Bone Marrow / immunology
  • CD8-Positive T-Lymphocytes* / immunology
  • Female
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / immunology
  • Leukemia, Myelomonocytic, Chronic* / drug therapy
  • Leukemia, Myelomonocytic, Chronic* / immunology
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes* / drug therapy
  • Myelodysplastic Syndromes* / immunology
  • Receptors, Antigen, T-Cell* / genetics
  • Receptors, Antigen, T-Cell* / immunology

Substances

  • Azacitidine
  • Receptors, Antigen, T-Cell